TOKYO, May 15 (Pulse News Wire) – Astellas Pharma Inc. (4503.T) extended its equity-based compensation plans through 2029, targeting executive officers and senior managers.
The plans aim to align employee incentives with long-term corporate value and shareholder returns. Key features include performance-linked stock awards and restricted stock units, with adjustments based on Total Shareholder Return relative to peer groups. The company also outlined criteria for eligibility and distribution schedules, emphasizing transparency and accountability. Under the new plan, eligible executives and senior managers will receive shares based on their roles and performance metrics.
The plan spans three fiscal years ending March 2029, with distributions tied to the company's TSR compared to the Nikkei index and global pharmaceutical peers. Adjustments will be made annually, ensuring alignment with competitive remuneration standards. In addition, Astellas established parameters for clawback provisions, allowing for the recovery of payments in cases of significant accounting errors or misconduct. The company emphasized adherence to ethical conduct and compliance with regulatory requirements throughout the program’s duration.
🟡 Confidence: Standard AI-translated content.